Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EyePoint, Inc.'s SEC filings document its business as a clinical-stage retinal-disease therapeutics company and record formal disclosures around DURAVYU, its investigational vorolanib intravitreal insert using Durasert E sustained-delivery technology. Form 8-K reports cover operating results, financial condition, cash resources, clinical-development updates for wet AMD and DME, investor presentations, and other material company events.
The company's proxy materials disclose governance, executive compensation, equity awards, shareholder voting matters, and board-related information. Additional filings record Nasdaq-listed common stock information, Regulation FD disclosures, forward-looking risk language, and legal-proceeding disclosures related to public statements about DURAVYU and its clinical results.
Schedule 13G/A (Amendment 1) filed for EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) discloses that Federated Hermes, Inc. and related reporting persons—Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue—collectively hold 4,599,450 shares of EyePoint common stock, representing 6.68 % of the outstanding class as of 30 June 2025.
The filing is made under Rule 13d-1(b) indicating a passive investment. Federated Hermes has sole voting and dispositive power over all reported shares; the individual Donahues share voting/dispositive power through the Trust. No other parties share control, and the group certifies the stake was acquired in the ordinary course of business with no intent to influence control of the issuer.
Key details for investors:
- Ownership threshold: Stake exceeds the 5 % reporting trigger, signalling meaningful institutional involvement.
- Aggregation structure: Shares are held via a Pennsylvania-based trust controlled by Federated Hermes executives, consolidating voting power.
- Certification: Reporting persons affirm the investment is non-activist and purely passive.
No financial performance data, purchase price or transaction timing beyond the “Date of Event” are provided.
EyePoint Pharmaceuticals President, CEO, and Director Jay S. Duker reported a significant insider transaction on June 23, 2025. The transaction involved the sale of 56,665 shares of common stock at $8.21 per share to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note valued at $465,219.65.
Following the transaction, Duker directly owns 986 shares and indirectly holds 99,165 shares through the Family Trust. The trust is managed by Duker's spouse as trustee and benefits their children. Notably, Duker has disclaimed beneficial ownership of the trust's securities.
Key transaction details:
- Transaction was executed under code 'J' (Other)
- Sale price determined by averaging high/low trading prices on transaction date
- Transaction represents a restructuring of ownership rather than a market sale
- Filing was signed by Ron Honig as Attorney-in-Fact on June 25, 2025